Cellectar Biosciences, Iopofosine I 131, Waldenström Macroglobulinemia, CLOVER WaM, BTK Inhibitors, BTKi-Resistant Cancer, Phase 2b Clinical Trial, Phase 3 Trial,

FLORHAM PARK, N.J., October 15, 2026 Cellectar Biosciences, Inc. (NASDAQ: CLRB) presented positive subgroup efficacy findings from its Phase...